| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085558737 |
| P356 | DOI | 10.1186/S12943-017-0660-5 |
| P932 | PMC publication ID | 5441085 |
| P698 | PubMed publication ID | 28532501 |
| P50 | author | Roch-Philippe Charles | Q38642441 |
| Michaela Medová | Q81652681 | ||
| P2093 | author name string | Roland Giger | |
| Yitzhak Zimmer | |||
| Michaela Poliaková | |||
| Daniel Matthias Aebersold | |||
| Paola Francica | |||
| Lluís Nisa | |||
| Pascal Häfliger | |||
| P2860 | cites work | mTOR signaling in growth control and disease | Q24634174 |
| Met in urological cancers | Q26864988 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence | Q27851725 | ||
| Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers | Q27852227 | ||
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors | Q27853166 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| Mapping the Pathways of Resistance to Targeted Therapies | Q28088791 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants | Q28254690 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101 | Q28678835 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy | Q31114634 | ||
| Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors | Q33929301 | ||
| mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations | Q34049613 | ||
| MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma | Q34182679 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells | Q34234737 | ||
| HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer | Q35174872 | ||
| PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting | Q35260766 | ||
| Retrospective Review of MET Gene Mutations | Q35745037 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition | Q36868012 | ||
| Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions | Q37161255 | ||
| Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. | Q37275769 | ||
| Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. | Q37301530 | ||
| The role of EGFR inhibition in the treatment of non-small cell lung cancer | Q37628306 | ||
| Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer | Q37817718 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside | Q38132874 | ||
| Targeting the MET gene for the treatment of non-small-cell lung cancer | Q38172700 | ||
| The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance | Q38175267 | ||
| KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. | Q38880117 | ||
| PIK3CA mutations in head and neck squamous cell carcinoma | Q40305620 | ||
| Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| A New Drug Combinatory Effect Prediction Algorithm on the Cancer Cell Based on Gene Expression and Dose-Response Curve | Q40678957 | ||
| New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors | Q41127315 | ||
| Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. | Q42506362 | ||
| The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. | Q42812957 | ||
| Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. | Q42833570 | ||
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib | Q45265090 | ||
| Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function | Q73759958 | ||
| A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head | Q86035602 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 93 | |
| P577 | publication date | 2017-05-22 | |
| P1433 | published in | Molecular Cancer | Q15724585 |
| P1476 | title | PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models | |
| P478 | volume | 16 |
| Q47162757 | Actionable mutations in canine hemangiosarcoma. |
| Q64926935 | Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer. |
| Q64238086 | Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma |
| Q64967099 | POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. |
| Q58566840 | The Role of PI3K in Met Driven Cancer: A Recap |
Search more.